Antelope DX finds series B sanctuary

Antelope DX, a Belgium-based sexually transmitted disease test producer spun out of Ghent University, has secured €9m ($10.7m) of series B capital from Whitefund and unnamed existing investors, Tech.eu has reported.
Founded in 2018, Antelope DX has built a lab-on-a-chip technology as the basis for urine testing for the sexually transmitted diseases Chlamydia trachomatis and Neisseria gonorrhoea.
The tests are described as being simply-to-use and affordable enough to be marketed to consumers.
Antelope DX is also working on lab-on-a-chip tests for Sars-Cov-2,  the coronavirus that causes covid-19, in addition to type A and B respiratory flu.
The spinout extends a decade of research at Ghent University’s Photonics Research Group in collaboration with biomedicine research assay provider MyCartis.
It previously received $5.9m in a mid-2019 series A round featuring RMM and Saffelberg in addition to assorted angel investors.